Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
Impax Laboratories
|
| gptkbp:acquisitionYear |
2018
|
| gptkbp:CEO |
Chirag Patel
Chintu Patel |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
biosimilars
specialty pharmaceuticals generic medicines |
| gptkbp:foundedBy |
Chirag Patel
Chintu Patel |
| gptkbp:foundedYear |
2002
|
| gptkbp:headquartersLocation |
gptkb:Bridgewater,_New_Jersey,_United_States
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:Adzenys_XR-ODT
Rytary Unithroid |
| gptkbp:numberOfEmployees |
approximately 6,000
|
| gptkbp:product |
generic drugs
specialty pharmaceuticals |
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockExchange |
gptkb:New_York_Stock_Exchange
|
| gptkbp:stockSymbol |
AMRX
|
| gptkbp:tradedOn |
NYSE: AMRX
|
| gptkbp:website |
https://www.amneal.com/
|
| gptkbp:bfsParent |
gptkb:Paul_Bisaro
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Amneal Pharmaceuticals
|